Skip to main content
. Author manuscript; available in PMC: 2017 Mar 10.
Published in final edited form as: Cancer. 2009 Sep 15;115(18):4136–4147. doi: 10.1002/cncr.24504

FIGURE 3.

FIGURE 3

The time to treatment failure is shown. This was defined as the time from randomization to disease progression, off-study or crossover, or death. Patients who had not crossed over to the alternate treatment arm or who were off study because of study closure were censored at the date of their last hematologic or cytogenetic assessment.